These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9155162)

  • 1. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
    Funato T
    Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reversal of drug resistance in human cancer cells by anti-oncogenes].
    Funato T
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):395-400. PubMed ID: 9063474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic applications of ribozymes.
    Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.
    Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T
    In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
    Kobayashi H; Takemura Y; Miyachi H
    Hum Cell; 2001 Sep; 14(3):172-84. PubMed ID: 11774737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Circumventing drug resistance in human tumors by antisense ribozyme].
    Funato T
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):336-42. PubMed ID: 8109989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
    Kaszubiak A; Holm PS; Lage H
    Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.
    Nagata J; Kijima H; Hatanaka H; Asai S; Miyachi H; Abe Y; Yamazaki H; Nakamura M; Watanabe N; Mine T; Kondo T; Scanlon KJ; Ueyama Y
    Int J Oncol; 2002 Nov; 21(5):1021-6. PubMed ID: 12370750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
    Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribozyme: a clinical tool.
    Khan AU
    Clin Chim Acta; 2006 May; 367(1-2):20-7. PubMed ID: 16426595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.
    Kwon BS; Jung HS; Song MS; Cho KS; Kim SC; Kimm K; Jeong JS; Kim IH; Lee SW
    Mol Ther; 2005 Nov; 12(5):824-34. PubMed ID: 16040278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA.
    Nosrati M; Li S; Bagheri S; Ginzinger D; Blackburn EH; Debs RJ; Kashani-Sabet M
    Clin Cancer Res; 2004 Aug; 10(15):4983-90. PubMed ID: 15297398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribozymes: applications to functional analysis and gene discovery.
    Shiota M; Sano M; Miyagishi M; Taira K
    J Biochem; 2004 Aug; 136(2):133-47. PubMed ID: 15496583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK; Nabissa PM; Reddy EP
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.
    Kobayashi H; Dorai T; Holland JF; Ohnuma T
    Cancer Res; 1994 Mar; 54(5):1271-5. PubMed ID: 8118816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosterically controllable maxizymes for molecular gene therapy.
    Iyo M; Kawasaki H; Taira K
    Curr Opin Mol Ther; 2002 Apr; 4(2):154-65. PubMed ID: 12044037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
    Li YL; Torchet C; Vergne J; Maurel MC
    Biochimie; 2007 Oct; 89(10):1257-63. PubMed ID: 17703868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.